Taking CAR-T Therapy to the Next Level is Part 2 of 3 of our most recent CAR-T series.  The dialogue is focused on moving from autologous to allogeneic approaches and from blood based cancer therapy to treating solid tumors.  The article also features a couple programs our panelists are actively working on that could change the outlook of CAR-T.

Moderator

• Shailesh Maingi, Founder and CEO, Kineticos

Panel Members

• Bill Farley, VP of Business and Corporate Development, Sorrento Therapeutics
• Anil Goyal, Chief Business Officer, MimiVax
• Michael Catelani, Chief Operating and Financial Officer, Anixa Biosciences

• Part 1 – CAR-T Therapy: Are We Getting a Bargain?

Subscribe to Kineticos to receive weekly emails containing insightful content.

0